nodes	percent_of_prediction	percent_of_DWPC	metapath
Valsartan—SLCO1B3—Methotrexate—testicular cancer	0.202	0.369	CbGbCtD
Valsartan—SLCO1B1—Methotrexate—testicular cancer	0.117	0.215	CbGbCtD
Valsartan—CYP2C9—Ifosfamide—testicular cancer	0.11	0.201	CbGbCtD
Valsartan—ALB—Methotrexate—testicular cancer	0.0643	0.118	CbGbCtD
Valsartan—CYP2C9—Cisplatin—testicular cancer	0.0534	0.0977	CbGbCtD
Valsartan—Abdominal pain upper—Doxorubicin—testicular cancer	0.000551	0.00122	CcSEcCtD
Valsartan—Photosensitivity reaction—Methotrexate—testicular cancer	0.00055	0.00121	CcSEcCtD
Valsartan—Anorexia—Etoposide—testicular cancer	0.000545	0.0012	CcSEcCtD
Valsartan—Decreased appetite—Cisplatin—testicular cancer	0.000543	0.0012	CcSEcCtD
Valsartan—Bronchitis—Epirubicin—testicular cancer	0.000542	0.0012	CcSEcCtD
Valsartan—Diarrhoea—Dactinomycin—testicular cancer	0.000541	0.00119	CcSEcCtD
Valsartan—Gastrointestinal disorder—Cisplatin—testicular cancer	0.000539	0.00119	CcSEcCtD
Valsartan—Vomiting—Bleomycin—testicular cancer	0.000539	0.00119	CcSEcCtD
Valsartan—Infestation NOS—Methotrexate—testicular cancer	0.000537	0.00118	CcSEcCtD
Valsartan—Infestation—Methotrexate—testicular cancer	0.000537	0.00118	CcSEcCtD
Valsartan—Hypotension—Etoposide—testicular cancer	0.000534	0.00118	CcSEcCtD
Valsartan—Rash—Bleomycin—testicular cancer	0.000534	0.00118	CcSEcCtD
Valsartan—Dermatitis—Bleomycin—testicular cancer	0.000534	0.00118	CcSEcCtD
Valsartan—Hypersensitivity—Ifosfamide—testicular cancer	0.000533	0.00118	CcSEcCtD
Valsartan—Muscular weakness—Doxorubicin—testicular cancer	0.000532	0.00117	CcSEcCtD
Valsartan—Renal failure—Methotrexate—testicular cancer	0.000528	0.00116	CcSEcCtD
Valsartan—Neutropenia—Epirubicin—testicular cancer	0.000527	0.00116	CcSEcCtD
Valsartan—Upper respiratory tract infection—Epirubicin—testicular cancer	0.000524	0.00116	CcSEcCtD
Valsartan—Asthenia—Ifosfamide—testicular cancer	0.000519	0.00115	CcSEcCtD
Valsartan—Photosensitivity reaction—Epirubicin—testicular cancer	0.000515	0.00113	CcSEcCtD
Valsartan—Paraesthesia—Etoposide—testicular cancer	0.000513	0.00113	CcSEcCtD
Valsartan—Pruritus—Ifosfamide—testicular cancer	0.000512	0.00113	CcSEcCtD
Valsartan—Dyspnoea—Etoposide—testicular cancer	0.00051	0.00112	CcSEcCtD
Valsartan—Somnolence—Etoposide—testicular cancer	0.000508	0.00112	CcSEcCtD
Valsartan—Epistaxis—Methotrexate—testicular cancer	0.000507	0.00112	CcSEcCtD
Valsartan—Nausea—Bleomycin—testicular cancer	0.000503	0.00111	CcSEcCtD
Valsartan—Infestation—Epirubicin—testicular cancer	0.000503	0.00111	CcSEcCtD
Valsartan—Infestation NOS—Epirubicin—testicular cancer	0.000503	0.00111	CcSEcCtD
Valsartan—Vomiting—Dactinomycin—testicular cancer	0.000502	0.00111	CcSEcCtD
Valsartan—Bronchitis—Doxorubicin—testicular cancer	0.000502	0.00111	CcSEcCtD
Valsartan—Rash—Dactinomycin—testicular cancer	0.000498	0.0011	CcSEcCtD
Valsartan—Decreased appetite—Etoposide—testicular cancer	0.000497	0.0011	CcSEcCtD
Valsartan—Diarrhoea—Ifosfamide—testicular cancer	0.000495	0.00109	CcSEcCtD
Valsartan—Renal failure—Epirubicin—testicular cancer	0.000494	0.00109	CcSEcCtD
Valsartan—Gastrointestinal disorder—Etoposide—testicular cancer	0.000494	0.00109	CcSEcCtD
Valsartan—Fatigue—Etoposide—testicular cancer	0.000493	0.00109	CcSEcCtD
Valsartan—Constipation—Etoposide—testicular cancer	0.000489	0.00108	CcSEcCtD
Valsartan—Neutropenia—Doxorubicin—testicular cancer	0.000488	0.00108	CcSEcCtD
Valsartan—Upper respiratory tract infection—Doxorubicin—testicular cancer	0.000485	0.00107	CcSEcCtD
Valsartan—Haemoglobin—Methotrexate—testicular cancer	0.000485	0.00107	CcSEcCtD
Valsartan—Hepatitis—Methotrexate—testicular cancer	0.000482	0.00106	CcSEcCtD
Valsartan—Haemorrhage—Methotrexate—testicular cancer	0.000482	0.00106	CcSEcCtD
Valsartan—Dizziness—Ifosfamide—testicular cancer	0.000479	0.00106	CcSEcCtD
Valsartan—Pharyngitis—Methotrexate—testicular cancer	0.000478	0.00106	CcSEcCtD
Valsartan—Urinary tract disorder—Methotrexate—testicular cancer	0.000476	0.00105	CcSEcCtD
Valsartan—Photosensitivity reaction—Doxorubicin—testicular cancer	0.000476	0.00105	CcSEcCtD
Valsartan—Epistaxis—Epirubicin—testicular cancer	0.000474	0.00105	CcSEcCtD
Valsartan—Urethral disorder—Methotrexate—testicular cancer	0.000473	0.00104	CcSEcCtD
Valsartan—Sinusitis—Epirubicin—testicular cancer	0.000472	0.00104	CcSEcCtD
Valsartan—Nausea—Dactinomycin—testicular cancer	0.000469	0.00104	CcSEcCtD
Valsartan—Gastrointestinal pain—Etoposide—testicular cancer	0.000468	0.00103	CcSEcCtD
Valsartan—Infestation NOS—Doxorubicin—testicular cancer	0.000465	0.00103	CcSEcCtD
Valsartan—Infestation—Doxorubicin—testicular cancer	0.000465	0.00103	CcSEcCtD
Valsartan—Vomiting—Ifosfamide—testicular cancer	0.00046	0.00102	CcSEcCtD
Valsartan—Hypersensitivity—Cisplatin—testicular cancer	0.00046	0.00101	CcSEcCtD
Valsartan—Renal failure—Doxorubicin—testicular cancer	0.000457	0.00101	CcSEcCtD
Valsartan—Rash—Ifosfamide—testicular cancer	0.000457	0.00101	CcSEcCtD
Valsartan—Dermatitis—Ifosfamide—testicular cancer	0.000456	0.00101	CcSEcCtD
Valsartan—Urticaria—Etoposide—testicular cancer	0.000454	0.001	CcSEcCtD
Valsartan—Haemoglobin—Epirubicin—testicular cancer	0.000453	0.001	CcSEcCtD
Valsartan—Rhinitis—Epirubicin—testicular cancer	0.000452	0.000998	CcSEcCtD
Valsartan—Abdominal pain—Etoposide—testicular cancer	0.000452	0.000997	CcSEcCtD
Valsartan—Haemorrhage—Epirubicin—testicular cancer	0.000451	0.000995	CcSEcCtD
Valsartan—Hepatitis—Epirubicin—testicular cancer	0.000451	0.000995	CcSEcCtD
Valsartan—Asthenia—Cisplatin—testicular cancer	0.000448	0.000988	CcSEcCtD
Valsartan—Pharyngitis—Epirubicin—testicular cancer	0.000448	0.000988	CcSEcCtD
Valsartan—Cardiac disorder—Methotrexate—testicular cancer	0.000447	0.000987	CcSEcCtD
Valsartan—Urinary tract disorder—Epirubicin—testicular cancer	0.000446	0.000983	CcSEcCtD
Valsartan—Connective tissue disorder—Epirubicin—testicular cancer	0.000443	0.000978	CcSEcCtD
Valsartan—Urethral disorder—Epirubicin—testicular cancer	0.000442	0.000975	CcSEcCtD
Valsartan—Epistaxis—Doxorubicin—testicular cancer	0.000439	0.000967	CcSEcCtD
Valsartan—Angiopathy—Methotrexate—testicular cancer	0.000437	0.000965	CcSEcCtD
Valsartan—Sinusitis—Doxorubicin—testicular cancer	0.000436	0.000962	CcSEcCtD
Valsartan—Immune system disorder—Methotrexate—testicular cancer	0.000435	0.00096	CcSEcCtD
Valsartan—Mediastinal disorder—Methotrexate—testicular cancer	0.000435	0.000958	CcSEcCtD
Valsartan—Nausea—Ifosfamide—testicular cancer	0.00043	0.000949	CcSEcCtD
Valsartan—Diarrhoea—Cisplatin—testicular cancer	0.000427	0.000942	CcSEcCtD
Valsartan—Alopecia—Methotrexate—testicular cancer	0.000426	0.00094	CcSEcCtD
Valsartan—Mental disorder—Methotrexate—testicular cancer	0.000422	0.000932	CcSEcCtD
Valsartan—Hypersensitivity—Etoposide—testicular cancer	0.000421	0.000929	CcSEcCtD
Valsartan—Malnutrition—Methotrexate—testicular cancer	0.00042	0.000926	CcSEcCtD
Valsartan—Haemoglobin—Doxorubicin—testicular cancer	0.00042	0.000925	CcSEcCtD
Valsartan—Cardiac disorder—Epirubicin—testicular cancer	0.000419	0.000924	CcSEcCtD
Valsartan—Rhinitis—Doxorubicin—testicular cancer	0.000419	0.000923	CcSEcCtD
Valsartan—Haemorrhage—Doxorubicin—testicular cancer	0.000417	0.000921	CcSEcCtD
Valsartan—Hepatitis—Doxorubicin—testicular cancer	0.000417	0.000921	CcSEcCtD
Valsartan—Pharyngitis—Doxorubicin—testicular cancer	0.000414	0.000914	CcSEcCtD
Valsartan—Urinary tract disorder—Doxorubicin—testicular cancer	0.000412	0.000909	CcSEcCtD
Valsartan—Dysgeusia—Methotrexate—testicular cancer	0.000411	0.000906	CcSEcCtD
Valsartan—Asthenia—Etoposide—testicular cancer	0.00041	0.000905	CcSEcCtD
Valsartan—Connective tissue disorder—Doxorubicin—testicular cancer	0.00041	0.000905	CcSEcCtD
Valsartan—Angiopathy—Epirubicin—testicular cancer	0.000409	0.000903	CcSEcCtD
Valsartan—Urethral disorder—Doxorubicin—testicular cancer	0.000409	0.000903	CcSEcCtD
Valsartan—Immune system disorder—Epirubicin—testicular cancer	0.000408	0.000899	CcSEcCtD
Valsartan—Mediastinal disorder—Epirubicin—testicular cancer	0.000407	0.000897	CcSEcCtD
Valsartan—Back pain—Methotrexate—testicular cancer	0.000406	0.000895	CcSEcCtD
Valsartan—Pruritus—Etoposide—testicular cancer	0.000405	0.000892	CcSEcCtD
Valsartan—Alopecia—Epirubicin—testicular cancer	0.000399	0.000879	CcSEcCtD
Valsartan—Vomiting—Cisplatin—testicular cancer	0.000397	0.000875	CcSEcCtD
Valsartan—Vision blurred—Methotrexate—testicular cancer	0.000396	0.000872	CcSEcCtD
Valsartan—Mental disorder—Epirubicin—testicular cancer	0.000395	0.000872	CcSEcCtD
Valsartan—Rash—Cisplatin—testicular cancer	0.000394	0.000868	CcSEcCtD
Valsartan—Dermatitis—Cisplatin—testicular cancer	0.000393	0.000867	CcSEcCtD
Valsartan—Malnutrition—Epirubicin—testicular cancer	0.000393	0.000866	CcSEcCtD
Valsartan—Diarrhoea—Etoposide—testicular cancer	0.000391	0.000863	CcSEcCtD
Valsartan—Cardiac disorder—Doxorubicin—testicular cancer	0.000387	0.000855	CcSEcCtD
Valsartan—Flatulence—Epirubicin—testicular cancer	0.000387	0.000854	CcSEcCtD
Valsartan—Dysgeusia—Epirubicin—testicular cancer	0.000385	0.000848	CcSEcCtD
Valsartan—Back pain—Epirubicin—testicular cancer	0.00038	0.000838	CcSEcCtD
Valsartan—Angiopathy—Doxorubicin—testicular cancer	0.000379	0.000835	CcSEcCtD
Valsartan—Dizziness—Etoposide—testicular cancer	0.000378	0.000834	CcSEcCtD
Valsartan—Muscle spasms—Epirubicin—testicular cancer	0.000378	0.000833	CcSEcCtD
Valsartan—Immune system disorder—Doxorubicin—testicular cancer	0.000377	0.000832	CcSEcCtD
Valsartan—Vertigo—Methotrexate—testicular cancer	0.000377	0.000832	CcSEcCtD
Valsartan—Mediastinal disorder—Doxorubicin—testicular cancer	0.000376	0.00083	CcSEcCtD
Valsartan—Nausea—Cisplatin—testicular cancer	0.000371	0.000818	CcSEcCtD
Valsartan—Vision blurred—Epirubicin—testicular cancer	0.00037	0.000816	CcSEcCtD
Valsartan—Alopecia—Doxorubicin—testicular cancer	0.000369	0.000814	CcSEcCtD
Valsartan—Cough—Methotrexate—testicular cancer	0.000366	0.000808	CcSEcCtD
Valsartan—Mental disorder—Doxorubicin—testicular cancer	0.000366	0.000807	CcSEcCtD
Valsartan—Vomiting—Etoposide—testicular cancer	0.000364	0.000802	CcSEcCtD
Valsartan—Malnutrition—Doxorubicin—testicular cancer	0.000363	0.000802	CcSEcCtD
Valsartan—Rash—Etoposide—testicular cancer	0.000361	0.000795	CcSEcCtD
Valsartan—Dermatitis—Etoposide—testicular cancer	0.00036	0.000795	CcSEcCtD
Valsartan—Headache—Etoposide—testicular cancer	0.000358	0.00079	CcSEcCtD
Valsartan—Flatulence—Doxorubicin—testicular cancer	0.000358	0.00079	CcSEcCtD
Valsartan—Chest pain—Methotrexate—testicular cancer	0.000357	0.000788	CcSEcCtD
Valsartan—Myalgia—Methotrexate—testicular cancer	0.000357	0.000788	CcSEcCtD
Valsartan—Arthralgia—Methotrexate—testicular cancer	0.000357	0.000788	CcSEcCtD
Valsartan—Dysgeusia—Doxorubicin—testicular cancer	0.000356	0.000785	CcSEcCtD
Valsartan—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—testicular cancer	0.000355	0.000783	CcSEcCtD
Valsartan—Vertigo—Epirubicin—testicular cancer	0.000353	0.000778	CcSEcCtD
Valsartan—Syncope—Epirubicin—testicular cancer	0.000352	0.000777	CcSEcCtD
Valsartan—Back pain—Doxorubicin—testicular cancer	0.000352	0.000775	CcSEcCtD
Valsartan—Muscle spasms—Doxorubicin—testicular cancer	0.000349	0.000771	CcSEcCtD
Valsartan—Palpitations—Epirubicin—testicular cancer	0.000347	0.000766	CcSEcCtD
Valsartan—Loss of consciousness—Epirubicin—testicular cancer	0.000345	0.000761	CcSEcCtD
Valsartan—Cough—Epirubicin—testicular cancer	0.000343	0.000756	CcSEcCtD
Valsartan—Anaphylactic shock—Methotrexate—testicular cancer	0.000343	0.000755	CcSEcCtD
Valsartan—Vision blurred—Doxorubicin—testicular cancer	0.000342	0.000755	CcSEcCtD
Valsartan—Infection—Methotrexate—testicular cancer	0.00034	0.000751	CcSEcCtD
Valsartan—Nausea—Etoposide—testicular cancer	0.00034	0.000749	CcSEcCtD
Valsartan—Nervous system disorder—Methotrexate—testicular cancer	0.000336	0.000741	CcSEcCtD
Valsartan—Thrombocytopenia—Methotrexate—testicular cancer	0.000335	0.00074	CcSEcCtD
Valsartan—Chest pain—Epirubicin—testicular cancer	0.000334	0.000738	CcSEcCtD
Valsartan—Arthralgia—Epirubicin—testicular cancer	0.000334	0.000738	CcSEcCtD
Valsartan—Myalgia—Epirubicin—testicular cancer	0.000334	0.000738	CcSEcCtD
Valsartan—Anxiety—Epirubicin—testicular cancer	0.000333	0.000735	CcSEcCtD
Valsartan—Skin disorder—Methotrexate—testicular cancer	0.000333	0.000734	CcSEcCtD
Valsartan—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—testicular cancer	0.000332	0.000732	CcSEcCtD
Valsartan—Dry mouth—Epirubicin—testicular cancer	0.000327	0.000721	CcSEcCtD
Valsartan—Vertigo—Doxorubicin—testicular cancer	0.000327	0.00072	CcSEcCtD
Valsartan—Anorexia—Methotrexate—testicular cancer	0.000326	0.00072	CcSEcCtD
Valsartan—Syncope—Doxorubicin—testicular cancer	0.000326	0.000719	CcSEcCtD
Valsartan—Palpitations—Doxorubicin—testicular cancer	0.000321	0.000708	CcSEcCtD
Valsartan—Oedema—Epirubicin—testicular cancer	0.000321	0.000707	CcSEcCtD
Valsartan—Anaphylactic shock—Epirubicin—testicular cancer	0.000321	0.000707	CcSEcCtD
Valsartan—Hypotension—Methotrexate—testicular cancer	0.00032	0.000706	CcSEcCtD
Valsartan—Loss of consciousness—Doxorubicin—testicular cancer	0.000319	0.000704	CcSEcCtD
Valsartan—Infection—Epirubicin—testicular cancer	0.000318	0.000702	CcSEcCtD
Valsartan—Cough—Doxorubicin—testicular cancer	0.000317	0.000699	CcSEcCtD
Valsartan—Shock—Epirubicin—testicular cancer	0.000315	0.000696	CcSEcCtD
Valsartan—Nervous system disorder—Epirubicin—testicular cancer	0.000314	0.000693	CcSEcCtD
Valsartan—Thrombocytopenia—Epirubicin—testicular cancer	0.000314	0.000692	CcSEcCtD
Valsartan—Musculoskeletal discomfort—Methotrexate—testicular cancer	0.000312	0.000688	CcSEcCtD
Valsartan—Skin disorder—Epirubicin—testicular cancer	0.000311	0.000687	CcSEcCtD
Valsartan—Insomnia—Methotrexate—testicular cancer	0.00031	0.000683	CcSEcCtD
Valsartan—Chest pain—Doxorubicin—testicular cancer	0.000309	0.000682	CcSEcCtD
Valsartan—Myalgia—Doxorubicin—testicular cancer	0.000309	0.000682	CcSEcCtD
Valsartan—Arthralgia—Doxorubicin—testicular cancer	0.000309	0.000682	CcSEcCtD
Valsartan—Anxiety—Doxorubicin—testicular cancer	0.000308	0.00068	CcSEcCtD
Valsartan—Paraesthesia—Methotrexate—testicular cancer	0.000308	0.000678	CcSEcCtD
Valsartan—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—testicular cancer	0.000307	0.000678	CcSEcCtD
Valsartan—Anorexia—Epirubicin—testicular cancer	0.000306	0.000674	CcSEcCtD
Valsartan—Dyspnoea—Methotrexate—testicular cancer	0.000305	0.000674	CcSEcCtD
Valsartan—Somnolence—Methotrexate—testicular cancer	0.000305	0.000672	CcSEcCtD
Valsartan—Dry mouth—Doxorubicin—testicular cancer	0.000303	0.000667	CcSEcCtD
Valsartan—Dyspepsia—Methotrexate—testicular cancer	0.000302	0.000665	CcSEcCtD
Valsartan—Hypotension—Epirubicin—testicular cancer	0.0003	0.000661	CcSEcCtD
Valsartan—Decreased appetite—Methotrexate—testicular cancer	0.000298	0.000657	CcSEcCtD
Valsartan—Oedema—Doxorubicin—testicular cancer	0.000297	0.000654	CcSEcCtD
Valsartan—Anaphylactic shock—Doxorubicin—testicular cancer	0.000297	0.000654	CcSEcCtD
Valsartan—Gastrointestinal disorder—Methotrexate—testicular cancer	0.000296	0.000652	CcSEcCtD
Valsartan—Fatigue—Methotrexate—testicular cancer	0.000295	0.000651	CcSEcCtD
Valsartan—Infection—Doxorubicin—testicular cancer	0.000295	0.00065	CcSEcCtD
Valsartan—Musculoskeletal discomfort—Epirubicin—testicular cancer	0.000292	0.000644	CcSEcCtD
Valsartan—Shock—Doxorubicin—testicular cancer	0.000292	0.000644	CcSEcCtD
Valsartan—Nervous system disorder—Doxorubicin—testicular cancer	0.000291	0.000642	CcSEcCtD
Valsartan—Thrombocytopenia—Doxorubicin—testicular cancer	0.00029	0.00064	CcSEcCtD
Valsartan—Insomnia—Epirubicin—testicular cancer	0.00029	0.000639	CcSEcCtD
Valsartan—Skin disorder—Doxorubicin—testicular cancer	0.000288	0.000635	CcSEcCtD
Valsartan—Paraesthesia—Epirubicin—testicular cancer	0.000288	0.000635	CcSEcCtD
Valsartan—Dyspnoea—Epirubicin—testicular cancer	0.000286	0.00063	CcSEcCtD
Valsartan—Somnolence—Epirubicin—testicular cancer	0.000285	0.000629	CcSEcCtD
Valsartan—Anorexia—Doxorubicin—testicular cancer	0.000283	0.000624	CcSEcCtD
Valsartan—Dyspepsia—Epirubicin—testicular cancer	0.000282	0.000622	CcSEcCtD
Valsartan—Gastrointestinal pain—Methotrexate—testicular cancer	0.00028	0.000618	CcSEcCtD
Valsartan—Decreased appetite—Epirubicin—testicular cancer	0.000279	0.000615	CcSEcCtD
Valsartan—Hypotension—Doxorubicin—testicular cancer	0.000277	0.000611	CcSEcCtD
Valsartan—Gastrointestinal disorder—Epirubicin—testicular cancer	0.000277	0.00061	CcSEcCtD
Valsartan—Fatigue—Epirubicin—testicular cancer	0.000276	0.00061	CcSEcCtD
Valsartan—Constipation—Epirubicin—testicular cancer	0.000274	0.000605	CcSEcCtD
Valsartan—Urticaria—Methotrexate—testicular cancer	0.000272	0.0006	CcSEcCtD
Valsartan—Abdominal pain—Methotrexate—testicular cancer	0.000271	0.000597	CcSEcCtD
Valsartan—Musculoskeletal discomfort—Doxorubicin—testicular cancer	0.00027	0.000596	CcSEcCtD
Valsartan—Insomnia—Doxorubicin—testicular cancer	0.000268	0.000592	CcSEcCtD
Valsartan—Paraesthesia—Doxorubicin—testicular cancer	0.000266	0.000587	CcSEcCtD
Valsartan—Dyspnoea—Doxorubicin—testicular cancer	0.000264	0.000583	CcSEcCtD
Valsartan—Somnolence—Doxorubicin—testicular cancer	0.000264	0.000582	CcSEcCtD
Valsartan—Gastrointestinal pain—Epirubicin—testicular cancer	0.000262	0.000578	CcSEcCtD
Valsartan—Dyspepsia—Doxorubicin—testicular cancer	0.000261	0.000576	CcSEcCtD
Valsartan—Decreased appetite—Doxorubicin—testicular cancer	0.000258	0.000569	CcSEcCtD
Valsartan—Gastrointestinal disorder—Doxorubicin—testicular cancer	0.000256	0.000565	CcSEcCtD
Valsartan—Fatigue—Doxorubicin—testicular cancer	0.000256	0.000564	CcSEcCtD
Valsartan—Urticaria—Epirubicin—testicular cancer	0.000255	0.000562	CcSEcCtD
Valsartan—Constipation—Doxorubicin—testicular cancer	0.000254	0.000559	CcSEcCtD
Valsartan—Abdominal pain—Epirubicin—testicular cancer	0.000253	0.000559	CcSEcCtD
Valsartan—Hypersensitivity—Methotrexate—testicular cancer	0.000252	0.000557	CcSEcCtD
Valsartan—Asthenia—Methotrexate—testicular cancer	0.000246	0.000542	CcSEcCtD
Valsartan—Gastrointestinal pain—Doxorubicin—testicular cancer	0.000243	0.000535	CcSEcCtD
Valsartan—Pruritus—Methotrexate—testicular cancer	0.000242	0.000534	CcSEcCtD
Valsartan—Hypersensitivity—Epirubicin—testicular cancer	0.000236	0.000521	CcSEcCtD
Valsartan—Urticaria—Doxorubicin—testicular cancer	0.000236	0.00052	CcSEcCtD
Valsartan—Abdominal pain—Doxorubicin—testicular cancer	0.000234	0.000517	CcSEcCtD
Valsartan—Diarrhoea—Methotrexate—testicular cancer	0.000234	0.000517	CcSEcCtD
Valsartan—Asthenia—Epirubicin—testicular cancer	0.00023	0.000507	CcSEcCtD
Valsartan—Pruritus—Epirubicin—testicular cancer	0.000227	0.0005	CcSEcCtD
Valsartan—Dizziness—Methotrexate—testicular cancer	0.000227	0.0005	CcSEcCtD
Valsartan—Diarrhoea—Epirubicin—testicular cancer	0.000219	0.000484	CcSEcCtD
Valsartan—Hypersensitivity—Doxorubicin—testicular cancer	0.000219	0.000482	CcSEcCtD
Valsartan—Vomiting—Methotrexate—testicular cancer	0.000218	0.00048	CcSEcCtD
Valsartan—Rash—Methotrexate—testicular cancer	0.000216	0.000476	CcSEcCtD
Valsartan—Dermatitis—Methotrexate—testicular cancer	0.000216	0.000476	CcSEcCtD
Valsartan—Headache—Methotrexate—testicular cancer	0.000215	0.000473	CcSEcCtD
Valsartan—Asthenia—Doxorubicin—testicular cancer	0.000213	0.000469	CcSEcCtD
Valsartan—Dizziness—Epirubicin—testicular cancer	0.000212	0.000468	CcSEcCtD
Valsartan—Pruritus—Doxorubicin—testicular cancer	0.00021	0.000463	CcSEcCtD
Valsartan—Vomiting—Epirubicin—testicular cancer	0.000204	0.00045	CcSEcCtD
Valsartan—Nausea—Methotrexate—testicular cancer	0.000203	0.000449	CcSEcCtD
Valsartan—Diarrhoea—Doxorubicin—testicular cancer	0.000203	0.000448	CcSEcCtD
Valsartan—Rash—Epirubicin—testicular cancer	0.000202	0.000446	CcSEcCtD
Valsartan—Dermatitis—Epirubicin—testicular cancer	0.000202	0.000445	CcSEcCtD
Valsartan—Headache—Epirubicin—testicular cancer	0.000201	0.000443	CcSEcCtD
Valsartan—Dizziness—Doxorubicin—testicular cancer	0.000196	0.000433	CcSEcCtD
Valsartan—Nausea—Epirubicin—testicular cancer	0.00019	0.00042	CcSEcCtD
Valsartan—Vomiting—Doxorubicin—testicular cancer	0.000189	0.000416	CcSEcCtD
Valsartan—Rash—Doxorubicin—testicular cancer	0.000187	0.000412	CcSEcCtD
Valsartan—Dermatitis—Doxorubicin—testicular cancer	0.000187	0.000412	CcSEcCtD
Valsartan—Headache—Doxorubicin—testicular cancer	0.000186	0.00041	CcSEcCtD
Valsartan—Nausea—Doxorubicin—testicular cancer	0.000176	0.000389	CcSEcCtD
